Exforge HCT 5 mg/160 mg/12.5 mg
Exforge HCT 5 mg/160 mg/12.5 mg is a medicine authorised by Swissmedic under authorisation number 59407. The authorisation holder is Novartis Pharma Schweiz AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 16 September 2009 and the authorisation is valid without a time limit. ATC code C09DX01 places the medicine in the group Agents acting on the renin-angiotensin system.
| Authorisation number | 59407 |
|---|---|
| Name | Exforge HCT 5 mg/160 mg/12.5 mg |
| Full name | Exforge HCT 5 mg/160 mg/12.5 mg, Filmtabletten |
| Authorisation holder | Novartis Pharma Schweiz AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | C09DX01 |
| First authorisation | 16 September 2009 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Exforge HCT 5 mg/160 mg/12.5 mg, Filmtabletten | B | 16 September 2009 |
| 2 | Exforge HCT 10 mg/160 mg/12.5 mg, Filmtabletten | B | 16 September 2009 |
| 3 | Exforge HCT 5 mg/160 mg/25 mg, Filmtabletten | B | 16 September 2009 |
| 4 | Exforge HCT 10 mg/160 mg/25 mg, Filmtabletten | B | 16 September 2009 |
| 5 | Exforge HCT 10 mg/320 mg/25 mg, Filmtabletten | B | 16 September 2009 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 28 | Tablette(n) | C09DX01 | 02.07.2. | B |
| 3 | 98 | Tablette(n) | C09DX01 | 02.07.2. | B |
| 7 | 28 | Tablette(n) | C09DX01 | 02.07.2. | B |
| 9 | 98 | Tablette(n) | C09DX01 | 02.07.2. | B |
| 4 | 28 | Tablette(n) | C09DX01 | 02.07.2. | B |
| 6 | 98 | Tablette(n) | C09DX01 | 02.07.2. | B |
| 10 | 28 | Tablette(n) | C09DX01 | 02.07.2. | B |
| 12 | 98 | Tablette(n) | C09DX01 | 02.07.2. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Exforge HCT 5 mg/160 mg/12.5 mg authorised in Switzerland?
Yes. Exforge HCT 5 mg/160 mg/12.5 mg is authorised by Swissmedic under authorisation number 59407, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Exforge HCT 5 mg/160 mg/12.5 mg have?
Exforge HCT 5 mg/160 mg/12.5 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Exforge HCT 5 mg/160 mg/12.5 mg?
The authorisation holder is Novartis Pharma Schweiz AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.